A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by activating the mother’s immune system to produce protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, exactly when they are most vulnerable to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence suggesting that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine at the recommended time, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when vaccinated four weeks before birth
- Antibodies from the mother transferred through placenta protect newborns from birth
- Coverage achievable with 2-week gap before premature birth
- Vaccination in the third trimester still provides significant protection for infants
Persuasive evidence from current research
The performance of the pregnancy RSV vaccine has been demonstrated through a comprehensive study conducted across England, examining data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90 per cent of all births during that six-month timeframe, providing robust and representative evidence of the vaccine’s real-world impact. The study’s findings have been endorsed by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The breadth of this investigation offers healthcare professionals and expectant parents with confidence in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.
The results paint a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This stark contrast highlights the vaccine’s critical role in protecting against serious illness in newborns. The drop in hospital admissions above 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings reinforce the importance of the vaccination programme introduced in the UK in 2024.
Study methodology and scope
The research analysed birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection levels and hospitalisations. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically significant and indicative of the general population, rather than individual cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to identify the shortest interval needed between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology assessed actual clinical results rather than experimental conditions, providing practical evidence of how the vaccine functions when administered across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the threats
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection causes inflammation deep within the lungs and airways, making it extremely challenging for vulnerable newborns to feed and breathe effectively. Parents often witness their babies struggling visibly, their chests rising whilst they attempt to draw sufficient oxygen into their compromised lungs. Whilst the majority of babies improve through supportive care, a modest yet notable group succumb from respiratory syncytial virus complications annually, making immunisation programmes a essential public health imperative for defending the youngest and most at-risk people in our communities.
- RSV triggers inflammation in lungs, resulting in serious respiratory problems in babies
- Nearly 50% of infants acquire the infection during their first few months alive
- Symptoms vary between mild colds to serious chest infections that threaten life requiring hospitalisation
- More than 20,000 UK infants require serious hospital care for RSV each year
- A small number of babies die from RSV related complications annually in the UK
Adoption rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have stressed the value of pregnant women receiving their jab at the ideal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that the timing is essential for guaranteeing newborns receive the strongest possible immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery offers approximately 85% protection, experts recommend women to get their vaccine as early as possible from 28 weeks of pregnancy forward to maximise the antibodies passed to their babies through the placenta.
The guidance from public health bodies remains clear: pregnant women should make a priority of vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst maintaining strong safeguarding for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional differences in vaccination
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others continue working to boost understanding and access to the jab. These regional differences demonstrate differences across healthcare infrastructure, engagement approaches, and community involvement initiatives, though the national data demonstrates robust and reliable protection regardless of geographical location.
- NHS trusts launching multiple messaging strategies to connect with women during pregnancy
- Inconsistencies across regions in immunisation take-up across England necessitate strategic intervention
- Regional health providers adapting programmes to meet specific population needs
Practical implications and parent viewpoints
The vaccine’s remarkable effectiveness translates into concrete gains for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the launch of this protective measure, the 80% decrease in admissions means thousands of infants spared from severe infection. Parents no more face the upsetting situation of seeing their babies gasping for air or struggle to eat, symptoms that characterise severe RSV infections. The vaccine has markedly changed the terrain of neonatal respiratory health, offering expectant mothers a preventative option to shield their youngest infants during those vital initial period.
For families like that of Malachi, whose acute RSV infection led to devastating brain damage, the vaccine’s introduction carries deep personal significance. His mother’s promotion of the jab underscores the transformative consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has given considerable reassurance to pregnant women during their late pregnancy, transforming what was once an unavoidable seasonal threat into a controllable health concern.